CytoDyn Inc. (CYDY)
| Market Cap | 311.54M -3.0% |
| Revenue (ttm) | n/a |
| Net Income | -58.58M |
| EPS | -0.04 |
| Shares Out | 1.47B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,006,809 |
| Open | 0.2180 |
| Previous Close | 0.2177 |
| Day's Range | 0.2120 - 0.2247 |
| 52-Week Range | 0.1829 - 0.3970 |
| Beta | 1.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 14, 2026 |
About CytoDyn
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is b... [Read more]
Financial Performance
Financial StatementsNews
CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
VANCOUVER, Washington, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mon...
CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role VANCOUVER, Washington, Oct. 19, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), ...
CytoDyn Transcript: Investor update
CLOVER data showed substantial early ctDNA declines and encouraging clinical observations in heavily pretreated colorectal cancer patients. Priorities include completing the study, advancing oncology trials and preparing for FDA discussions; Robert Hoffman is taking over as CEO.
CytoDyn Proxy statement: Proxy filing
CytoDyn filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
CytoDyn to Host Investor Webcast
VANCOUVER, Wash., Oct. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclon...
CytoDyn Quarterly report: Q1 2027
CytoDyn has published its Q1 2027 quarterly earnings report on October 14, 2026.
CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
VANCOUVER, Washington, Oct. 08, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mon...
CytoDyn Proxy statement: Proxy filing
CytoDyn filed a proxy statement on September 28, 2026, providing details for shareholder voting and corporate governance matters.
CytoDyn Registration statement: Registration filing
CytoDyn filed a registration statement on September 25, 2026, providing details about a securities offering with the SEC.
CytoDyn Transcript: Life Sciences Virtual Investor Forum Conference
Leronlimab shows strong early efficacy and safety in metastatic colorectal cancer, with rapid enrollment and significant ctDNA reductions. Strategic collaboration with Natera enhances data analysis, and retrospective breast cancer data highlight long-term survival benefits. Multiple upcoming milestones and active partnering efforts are underway.
CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclo...
CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab
VANCOUVER, Washington, Sept. 01, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized mo...
CytoDyn Annual report: Q4 2026
CytoDyn has published its Q4 2026 annual report on August 31, 2026.
CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease
Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11, 2...
Natera, CytoDyn collaborate to advance ctDNA-guided development
Natera (NTRA) and CytoDyn Inc. (CYDY) announced a strategic collaboration to evaluate circulating tumor DNA dynamics and generate real-world molecular insights to support CytoDyn’s metastatic colorect...
CytoDyn Transcript: 16th Annual LD Micro Invitational Conference
Leronlimab is advancing through phase II trials in colorectal cancer, with rapid enrollment and promising early ctDNA and tumor response data. Retrospective results in triple-negative breast cancer are strong, and new studies are planned. Large market opportunities and regulatory milestones are targeted in 2024.
CytoDyn to Present at the LD Micro Invitational XVI
CFO Robert E. Hoffman to deliver company presentation on May 18 at 10 a.m.
CytoDyn Transcript: Study update
The CLOVER Phase II study in metastatic colorectal cancer shows promising early results, with all patients experiencing ctDNA declines and most achieving tumor shrinkage or stable disease. Leronlimab showed a strong safety profile and potential efficacy, even in KRAS-mutant cases. Upcoming milestones include expanded access in breast cancer and new trials.
CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer
Program provides access to leronlimab for patients with limited treatment options while supporting ongoing clinical development
CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026
Ongoing Phase 2 study in metastatic colorectal cancer (mCRC) demonstrates early clinical and biomarker activity with leronlimab in combination with TAS-102 and bevacizumab, supporting CCR5 as a therap...
CytoDyn Registration statement: Registration filing
CytoDyn filed a registration statement on April 22, 2026, providing details about a securities offering with the SEC.
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States
CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026
Translational study in metastatic triple-negative breast cancer (mTNBC) shows leronlimab-mediated CCR5 inhibition induces PD-L1 expression, modulates immune checkpoint signaling, and is associated wit...
CytoDyn to Present at the AACR Annual Meeting 2026
VANCOUVER, Wash., April 14, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclo...
CytoDyn Quarterly report: Q3 2026
CytoDyn has published its Q3 2026 quarterly earnings report on April 8, 2026.